financing characteristics

Sanofi backs $90M financing for I&I biologic developer

1 week ago talkbio0Tagged financing characteristics, I&I, sanofi, Series

sanofi, Series, financing characteristics, II

nChroma Bio Emerges from Chroma Medicine and Nvelop Therapeutics Merger, Secures $75 Million to Advance Genetic Medicines

4 months ago talkbio0Tagged Biotechnology, Chroma Medicine, epigenetic editing, financing characteristics, genetic medicines, Merger, nChroma, Non-Viral Delivery

nChroma Bio, Chroma Medicine, Nvelop Therapeutics, Genetic Medicines, Epigenetic Editing, Non-Viral Delivery, Biotechnology, Merger, Financing

Blue Earth Therapeutics Advances with $76.5M Series A Financing for Next-Gen Radiohybrid RLTs

6 months ago talkbio0Tagged Blue color, cellular targeting, financing characteristics, Greek letter alpha (qualifier value), lutetium, Phase II studies, RLTs

Blue Earth Therapeutics, Series A financing, radiohybrid RLTs, Phase II studies, targeted therapies, lutetium, alpha emitter.

Inventiva Secures Up to €348 Million in Financing to Advance Lanifibranor for MASH Treatment

6 months ago talkbio0Tagged Biological Factors, Clinical Trials, financing characteristics, Inventiva, lanifibranor, MASH, metabolic dysfunction-associated steatohepatitis, Phase 3

Inventiva, Lanifibranor, MASH (Metabolic Dysfunction-Associated Steatohepatitis), Phase 3 NATiV3 Clinical Trial, Financing, Biopharmaceutical

23andMe Board Rejects CEO Anne Wojcicki’s Take-Private Plan, Requests Changes

9 months ago talkbio0Tagged Anne Wojcicki, board rejection, financing characteristics, Prices, shareholders, take-private plan

23andMe, Anne Wojcicki, take-private plan, board rejection, financing, stock price, shareholders

Autobahn Therapeutics Advances to Phase II for Mood Disorders with $100M Financing

9 months ago talkbio0Tagged Autobahn Therapeutics, Drug Industry, financing characteristics, Phase II

Autobahn Therapeutics, Phase II, Mood Disorders, Financing, Pharmaceutical Industry

Myricx Bio Secures £90m ($114m) Series A Financing to Advance Novel NMTi ADC Therapeutics

10 months ago talkbio0Tagged Bio, Eli Lilly, financing characteristics, Holdings, Malignant Neoplasms, Myricx, NMTi, Series, therapeutic autologous dendritic cells

Myricx Bio, Series A Financing, NMTi ADC Therapeutics, Novo Holdings, Lilly, Cancer Treatment

ArriVent Expands ADC Portfolio with $615 Million Alphamab Acquisition

11 months ago talkbio0Tagged Acquisition (action), Alphamab, ArriVent, Biotechnology, financing characteristics, portfolio, therapeutic autologous dendritic cells

ArriVent, ADC portfolio, Alphamab, acquisition, biotech, biotechnology, financing

Galapagos Partners with Adaptimmune for $665M T-Cell Therapy Collaboration

11 months ago talkbio0Tagged Adaptimmune, biobucks, Collaboration, financing characteristics, Galapagos, Licensing, Melanoma-Associated Antigen 4, next-generation therapy, T-Cell Receptor, T-cell therapy

Galapagos, Adaptimmune, T-cell therapy, MAGE-A4 TCR, Uza-cel, Biobucks collaboration, Licensing deal, Financing, Next-generation therapy

Clasp Therapeutics Launches with $150M Series A Funding to Develop Next-Generation T Cell Engaging Immunotherapies

1 year ago talkbio0Tagged Ataxia Telangiectasia Mutated Proteins, Catalio Capital Management, cellular targeting, CEO, CLASRP gene, engagers, financing characteristics, HLA Molecule Profiling, Holdings, Personalized Off-the-Shelf Therapies, Robert Ross, T-Lymphocyte, Third Rock

Clasp Therapeutics, $150M Series A Financing, T Cell Engagers, Personalized Off-the-Shelf Therapies, Targeting Mutated Protein Fragments, HLA Molecule Profiling, Novo Holdings/ Third Rock Ventures/ Catalio Capital Management, CEO Robert Ross